Mary Haak-Frendscho, PhD

Dr. Mary Haak-Frendscho has served on our Board since March 2021. Dr. Haak-Frendscho served as the President and Chief Executive Officer of Spotlight Therapeutics, Inc., a privately held biotechnology company, until December 2024. Prior to Spotlight, from January 2017 to January 2019, She was a venture partner with Versant Venture Management, LLC and, from January 2016 to January 2019, she served as the Chief Executive Officer of Blueline Bioscience, Versant’s vehicle for new company creation in Canada.  Earlier, Dr. Haak-Frendscho established and served as the Chair of Compugen USA,  Inc. from 2012 to 2016, was the Chief Executive Officer of Igenica Biotherapeutics, Inc. from 2012 to 2014, and was the Founding President and Chief Scientific Officer of Takeda San Francisco, Innc. From 2008 to 2012.  Dr. Haak-Frendscho received her B.S. from the University of Michigan, M.L.A. from Washington University, M.D. from SUNY-Stony Brook, C.S.E.P. from Columbia University Graduate School of Business and Ph.D. from the University of Wisconsin.